XML 29 R35.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Acquisitions (Narrative) (Details) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2011
Feb. 28, 2011
Costs related to the acquisition $ 1,000,000 $ 10,928,000  
Contingent consideration 17,601,000 17,601,000  
Increase in fair value of contingent consideration   881,000  
Taligen Therapeutics, Inc [Member] | Purchased Technology [Member]
     
Intangible assets 5,000,000 5,000,000  
Taligen Therapeutics, Inc [Member] | In-process Research and Development [Member]
     
Non-amortizable intangible assets 59,500,000 59,500,000  
Orphatec Pharmaceuticals GmbH [Member] | In-process Research and Development [Member]
     
Non-amortizable intangible assets 8,050,000 8,050,000  
Taligen Therapeutics, Inc [Member] | Maximum [Member]
     
Contingent milestone payments 367,000,000 367,000,000  
Orphatec Pharmaceuticals GmbH [Member] | Maximum [Member]
     
Contingent milestone payments 42,000,000 42,000,000  
Taligen Therapeutics, Inc [Member] | Minimum [Member]
     
Contingent milestone payments 0 0  
Orphatec Pharmaceuticals GmbH [Member] | Minimum [Member]
     
Contingent milestone payments 0 0  
Taligen Therapeutics, Inc [Member]
     
Initial payments on acquisition 111,773,000 111,773,000  
Contingent milestone payments 367,000,000 367,000,000  
Costs related to the acquisition 707,000 10,076,000  
Fair value of contingent consideration 11,634,000 11,634,000  
Rate for discounting contingent consideration cash flows   4.90%  
Contingent consideration 12,384,000 12,384,000  
Increase in fair value of contingent consideration 1,321,000    
Purchased technology, estimated useful life (In years)   12  
Rate of return on historical costs   25.00%  
Deferred tax liability 9,959,000 9,959,000  
Deferred tax liability related to IPR&D 21,537,000 21,537,000  
Deferred tax liability related to net operating losses and research credit carryovers 13,338,000 13,338,000  
Orphatec Pharmaceuticals GmbH [Member]
     
Initial payments on acquisition 3,050,000 3,050,000 3,050,000
Contingent milestone payments 42,000,000 42,000,000  
Costs related to the acquisition 293,000 852,000  
Fair value of contingent consideration 5,086,000 5,086,000  
Contingent consideration $ 5,217,000 $ 5,217,000  
Weighted cash flow discount rate for development milestones   4.90%  
Weighted cash flow discount rate for commercial milestones   21.00%  
Present value discount rate   23.00%